# HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

> **NCT07296341** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Pancreatic Cancer With

## Interventions

- **DRUG:** HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine
- **DRUG:** HRS-4642;nab-paclitaxel; gemcitabine

## Key facts

- **NCT ID:** NCT07296341
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07296341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07296341, "HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07296341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*